Literature DB >> 12377849

The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ).

Lee J Dowson1, Peter J Guest, Robert A Stockley.   

Abstract

STUDY
OBJECTIVES: First, to determine the relationships among chronic sputum expectoration (CSE), exacerbations, airflow obstruction, and emphysema in patients with alpha(1)-antitrypsin deficiency (alpha(1)-ATD) [PiZ]. Second, to use multivariate analysis to determine how these factors influence health status.
DESIGN: Cross-sectional, single-center.
SETTING: UK center for alpha(1)-ATD, university teaching hospital. PATIENTS: One hundred seventeen nonsmoking patients underwent lung function testing, high-resolution CT (HRCT) scanning with density mask analysis, and health status assessment using the St. George's Respiratory Questionnaire (SGRQ) and short form 36 (SF-36) health survey questionnaire.
RESULTS: Patients with CSE (n = 50) had worse postbronchodilator airflow obstruction than those who did not (p = 0.03), with a median FEV(1) of 1.15 L (interquartile range [IQR], 0.76 to 1.82) vs 1.44 L (IQR, 0.99 to 2.93), respectively, and higher HRCT scan voxel index (VI) values indicating more extensive emphysema (patients with CSE: median lower zone VI, 50; IQR, 28 to 61; patients without CSE: median lower zone VI, 41; IQR, 5 to 53; p = 0.04). Patients with CSE also had worse health status, as assessed by the SGRQ (p < 0.01 for all domains) and SF-36 questionnaire (p < 0.05 for seven of nine domains). Exacerbation frequency was greater in those patients with CSE (p < 0.001), with a median of two episodes per year (IQR, 1 to 3) vs 0.66 episodes per year (IQR, 0 to 2) for those without CSE. Stepwise linear regression analysis revealed FEV(1), exacerbation frequency, and lower zone VI to be the most important predictors of health status.
CONCLUSIONS: Among patients with alpha(1)-ATD, those with CSE expectoration exhibit greater physiologic impairment and more extensive emphysema than those without. This is reflected in an inferior health status, which is also influenced independently by an increased exacerbation frequency in those with CSE.

Entities:  

Mesh:

Year:  2002        PMID: 12377849     DOI: 10.1378/chest.122.4.1247

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Authors:  Daniel J Smith; Paul R Ellis; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

2.  Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Authors:  Dawn L Demeo; Robert A Sandhaus; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen Rennard; Esteban Burchard; James M Stocks; James K Stoller; Charlie Strange; Gerard M Turino; Edward J Campbell; Edwin K Silverman
Journal:  Thorax       Date:  2007-03-27       Impact factor: 9.139

3.  Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency.

Authors:  Tsuneo Yamashiro; Shin Matsuoka; Raúl San José Estépar; Alejandro Diaz; John D Newell; Robert A Sandhaus; Patricia J Mergo; Mark L Brantly; Sadayuki Murayama; John J Reilly; Hiroto Hatabu; Edwin K Silverman; George R Washko
Journal:  COPD       Date:  2009-12       Impact factor: 2.409

Review 4.  Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history.

Authors:  M Needham; R A Stockley
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

Review 5.  Bronchiectasis in older patients with chronic obstructive pulmonary disease : prevalence, diagnosis and therapeutic management.

Authors:  Deborah Whitters; Robert A Stockley
Journal:  Drugs Aging       Date:  2013-04       Impact factor: 3.923

Review 6.  Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations.

Authors:  C M Greene; S D W Miller; T Carroll; C McLean; M O'Mahony; M W Lawless; S J O'Neill; C C Taggart; N G McElvaney
Journal:  J Inherit Metab Dis       Date:  2008-01-16       Impact factor: 4.982

7.  The patient profile of individuals with Alpha-1 antitrypsine gene mutations at a referral center in Brazil.

Authors:  Manuela Brisot Felisbino; Frederico Leon Arrabal Fernandes; Maria Cecília Nieves Maiorano de Nucci; Regina Maria de Carvalho Pinto; Emilio Pizzichini; Alberto Cukier
Journal:  J Bras Pneumol       Date:  2018 Sep-Oct       Impact factor: 2.624

8.  Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report.

Authors:  Sabri Denden; Michele Zorzetto; Fethi Amri; Jalel Knani; Stefania Ottaviani; Roberta Scabini; Marina Gorrini; Ilaria Ferrarotti; Ilaria Campo; Jemni Ben Chibani; Amel Haj Khelil; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2009-04-15       Impact factor: 4.123

Review 9.  Lung microbiology and exacerbations in COPD.

Authors:  Victoria Beasley; Priya V Joshi; Aran Singanayagam; Philip L Molyneaux; Sebastian L Johnston; Patrick Mallia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-08-31

Review 10.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach.

Authors:  Robert A Stockley; Marc Miravitlles; Claus Vogelmeier
Journal:  Orphanet J Rare Dis       Date:  2013-09-24       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.